| scholarly article | Q13442814 |
| P356 | DOI | 10.3233/JAD-150469 |
| P698 | PubMed publication ID | 26402114 |
| P50 | author | Laurence Fenart | Q52148936 |
| Fabien Gosselet | Q38801251 | ||
| P2093 | author name string | Marie-Christine Boucau | |
| Mélanie Kuntz | |||
| Emmanuel Sevin | |||
| Pietra Candela | |||
| Julien Saint-Pol | |||
| Yordenca Lamartinière | |||
| P2860 | cites work | Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease | Q22248076 |
| ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells | Q24305511 | ||
| Molecular interactions between apoE and ABCA1: impact on apoE lipidation | Q24306797 | ||
| ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models | Q24628845 | ||
| A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease | Q28261647 | ||
| The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease | Q28294536 | ||
| Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study | Q28366850 | ||
| Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". | Q50963355 | ||
| Peripheral reduction of β-amyloid is sufficient to reduce brain β-amyloid: implications for Alzheimer's disease. | Q53317230 | ||
| The RXR Agonist Bexarotene Improves Cholesterol Homeostasis and Inhibits Atherosclerosis Progression in a Mouse Model of Mixed Dyslipidemia | Q57244233 | ||
| A stable and reproducible human blood-brain barrier model derived from hematopoietic stem cells | Q28539764 | ||
| Improved survival, vascular differentiation and wound healing potential of stem cells co-cultured with endothelial cells | Q28743314 | ||
| Comment on "ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models" | Q29013008 | ||
| Comment on "ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models" | Q29543792 | ||
| Alzheimer's disease: the amyloid cascade hypothesis | Q29547160 | ||
| The blood-brain barrier in health and chronic neurodegenerative disorders | Q29616411 | ||
| Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function | Q30486577 | ||
| ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice | Q30497102 | ||
| Bexarotene reduces blood-brain barrier permeability in cerebral ischemia-reperfusion injured rats | Q30924126 | ||
| Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later | Q33621287 | ||
| Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway | Q33676328 | ||
| Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites | Q33832954 | ||
| Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease | Q33862071 | ||
| In vitro model for evaluating drug transport across the blood-brain barrier | Q33904239 | ||
| Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model | Q33915820 | ||
| Modelling of the blood-brain barrier in drug discovery and development. | Q34005458 | ||
| Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice | Q34212267 | ||
| Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis | Q35601755 | ||
| Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease | Q36229619 | ||
| Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease - implications for a new therapeutic approach. | Q36789913 | ||
| Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, and Alzheimer's disease | Q36818632 | ||
| Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice | Q36822983 | ||
| Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice | Q36958249 | ||
| The role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegeneration | Q37017266 | ||
| Amyloid-β peptides, Alzheimer's disease and the blood-brain barrier. | Q38155194 | ||
| Effects of oxysterols on the blood-brain barrier: implications for Alzheimer's disease. | Q38166085 | ||
| The emerging role of bexarotene in the treatment of Alzheimer's disease: current evidence | Q38364682 | ||
| ABCB1, ABCC1, and LRP gene expressions are altered by LDL, HDL, and serum deprivation in a human doxorubicin-resistant uterine sarcoma cell line. | Q38918413 | ||
| Stimulation of the retinoid X receptor facilitates beta-amyloid clearance across the blood-brain barrier | Q39297983 | ||
| P-glycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-beta | Q39860990 | ||
| Expression of nuclear receptor mRNA and liver X receptor-mediated regulation of ABC transporter A1 at rat blood-brain barrier | Q40071369 | ||
| Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-beta peptide generation | Q40205410 | ||
| 24S-hydroxycholesterol induces cholesterol release from choroid plexus epithelial cells in an apical- and apoE isoform-dependent manner concomitantly with the induction of ABCA1 and ABCG1 expression | Q40209163 | ||
| In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis | Q40276692 | ||
| Purification and ATPase activity of human ABCA1. | Q40311731 | ||
| Cholesterol modulates P-glycoprotein activity in human peripheral blood mononuclear cells | Q40576509 | ||
| P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model | Q41844698 | ||
| Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease | Q43286507 | ||
| Oxysterols decrease apical-to-basolateral transport of Aß peptides via an ABCB1-mediated process in an in vitro Blood-brain barrier model constituted of bovine brain capillary endothelial cells. | Q43465871 | ||
| Intercommunications between brain capillary endothelial cells and glial cells increase the transcellular permeability of the blood-brain barrier during ischaemia. | Q44208827 | ||
| RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain | Q44479225 | ||
| Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". | Q45080391 | ||
| DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice | Q46171098 | ||
| Transcriptional profiles of receptors and transporters involved in brain cholesterol homeostasis at the blood-brain barrier: use of an in vitro model. | Q46256906 | ||
| Accumulation of murine amyloid-β mimics early Alzheimer's disease. | Q46726629 | ||
| The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. | Q46738144 | ||
| Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease | Q46738145 | ||
| Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice | Q46738149 | ||
| Regulatory effects of synthetic liver X receptor- and peroxisome-proliferator activated receptor agonists on sterol transport pathways in polarized cerebrovascular endothelial cells | Q46985780 | ||
| Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene. | Q47767946 | ||
| Altered cerebral vascular volumes and solute transport at the blood-brain barriers of two transgenic mouse models of Alzheimer's disease | Q47898570 | ||
| Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol | Q48161830 | ||
| Modelling the neurovascular unit and the blood-brain barrier with the unique function of pericytes. | Q48823131 | ||
| Liver X receptor activation enhances blood-brain barrier integrity in the ischemic brain and increases the abundance of ATP-binding cassette transporters ABCB1 and ABCC1 on brain capillary cells | Q49036874 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P921 | main subject | blood–brain barrier | Q221694 |
| P304 | page(s) | 849-862 | |
| P577 | publication date | 2015-09-11 | |
| P1433 | published in | Journal of Alzheimer's Disease | Q6294755 |
| P1476 | title | Bexarotene Promotes Cholesterol Efflux and Restricts Apical-to-Basolateral Transport of Amyloid-β Peptides in an In Vitro Model of the Human Blood-Brain Barrier. | |
| P478 | volume | 48 |
| Q91646694 | Alteration in the Function and Expression of SLC and ABC Transporters in the Neurovascular Unit in Alzheimer's Disease and the Clinical Significance |
| Q94517987 | Axl receptor tyrosine kinase is a regulator of apolipoprotein E |
| Q88324973 | Bexarotene Modulates Retinoid-X-Receptor Expression and Is Protective Against Neurotoxic Endoplasmic Reticulum Stress Response and Apoptotic Pathway Activation |
| Q99238065 | Blood-Brain Barrier: More Contributor to Disruption of Central Nervous System Homeostasis Than Victim in Neurological Disorders |
| Q92061776 | Caco-2 Cells for Measuring Intestinal Cholesterol Transport - Possibilities and Limitations |
| Q28071254 | Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases |
| Q39005365 | Do Cancer Drugs Counteract Neurodegeneration? Repurposing for Alzheimer's Disease. |
| Q89550618 | Ketone Bodies Promote Amyloid-β1-40 Clearance in a Human in Vitro Blood-Brain Barrier Model |
| Q91803007 | PMP22 Regulates Cholesterol Trafficking and ABCA1-Mediated Cholesterol Efflux |
| Q47322495 | PPARδ activation by bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis |
| Q37210123 | ST6GALNAC5 Expression Decreases the Interactions between Breast Cancer Cells and the Human Blood-Brain Barrier. |
| Q35950790 | Selection of a Relevant In Vitro Blood-Brain Barrier Model to Investigate Pro-Metastatic Features of Human Breast Cancer Cell Lines |
| Q38760636 | The pleiotropic vasoprotective functions of high density lipoproteins (HDL). |
| Q41862906 | β-Cyclodextrins Decrease Cholesterol Release and ABC-Associated Transporter Expression in Smooth Muscle Cells and Aortic Endothelial Cells |
Search more.